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Abstracts
tively short duration and therefore cannot directly mea-
sure the long-term impact of therapies.
OBJECTIVE: To develop a flexible and comprehensive
tool to assist rapid outcome evaluation of potential inter-
ventions in stroke care in four countries: France, Ger-
many, UK, US.
METHODS: Decision-analytic software was used to con-
struct a Stroke Outcome Model, which consists of 4 inter-
related modules: (1) primary prevention; (2) "bridge" to
acute care; (3) acute care (ischaemic stroke only); and (4)
long-term care/prevention of recurrence in stroke survi-
vors. Stroke prevention was represented by Markov state
transition processes, states being defined in terms of use of
therapy, disability and occurrence of (further) stroke. Data
sources included clinical trials and meta-analyses, and pro-
spective cohorts: Framingham study, Oxford Community
Stroke Project and North Manhattan Stroke Study. Re-
source use data were obtained from published sources,
supplemented by in-country panels of clinical experts, and
unit costs from relevant national sources.
RESULTS/DISCUSSION: The modelling approach has
enabled the long-term consequences of acute or preven-
tive therapy to be evaluated. Analyses have examined the
cost-effectiveness of: antiplatelets in prevention of stroke
recurrence; thrombolytic therapy in acute stroke; and
stroke units. Results were sensitive to the duration of fol-
low-up and the cost perspective chosen, in particular
whether long-term care costs were included. The model
enables users to explore issues such as the choice of effec-
tiveness parameter or background event risks, and how
risks are projected beyond the follow-up periods reported
in trials or prospective studies. More data are required on
long-term care, disability and quality of life/utility, and
adjusted risks for (first) stroke.
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Studies with classical clinical endpoints indicated compa-
rable efficacy and tolerability of the two loop diuretics to-
rasemide and furosemide in congestive heart failure
(CHF). However, differences in the pharmacological pro-
files suggested potentially different quality of disease con-
trol under real life conditions.
OBJECTIVE: The present study aimed at collecting data
in a naturalistic setting and comparing overall cost and
cost-effectiveness of torasemide and furosemide.
METHODS: Data on the course of the disease and on re-
lated resource utilization were collected retrospectively
from a one-year treatment period of 200 torasernide-
treated and 200 furosemide-treated patients. High com-
parability of the two patient groups was achieved by us-
ing the matched-pair method with nine demographic and
medical matching criteria.
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RESULTS: Disease control was better in the torasemide
patients, as reflected by fewer hospital days due to CHF
(324 vs. 62) and more patients with improvement of
NYHA class (torasemide: 38.0% [31.25%-45.11 %]; fu-
rosemide: 24.5% [18.71 %-31.06%]) during the observa-
tion period. Comparing overall cost from the statutory
health insurance's perspective, torasemide treatment is
less costly by 361 DEM per patient and year (1502 vs.
1863 DEM). Moreover, torasemide is clearly more cost-
effective: The cost per patient with improved NYHA
class is 3954 DEM for torasemide versus 7605 DEM for
furosemide. Analyses from the societal perspective
yielded similar results.
CONCLUSIONS: The data reveal substantial improvement
of disease control and reduction of treatment cost with to-
rasemide compared to furosemide. Furthermore, this study
highlights the value of collecting naturalistic data from bal-
anced populations to improve our understanding of drug ef-
fects on disease courses and health care cost.
pews
READINESS TO COMPLY AND OUTCOMES OF
ANTIHYPERTENSIVE THERAPY
Garfield FB', Willey C2, Stafford J3, Redding 0, Caro JJ'
'Caro Research, Boston, MA, USA; 2University of Rhode Island,
Kingston, RI, USA; 3Bristol-Myers Squibb/Sanofi Pharma,
Princeton, NJ, USA
Since noncompliance is a major factor in the outcomes of
drug therapy for chronic conditions like hypertension, im-
proving compliance improves the outcomes of therapy. Re-
search with hypertensive patients has found more than
50% are noncompliant. Adherence to a medication regi-
men requires patients to change their behavior. Research
on a range of behaviors from smoking cessation to adopt-
ing an exercise program has found behavior change is a
process and individuals have different readiness to change.
OBJECTIVE: Examine how readiness to comply, pro-
cesses of change, temptations to be noncompliant, and
patients' views of the pros and cons of compliance are re-
lated to self-reported compliance.
METHODS: Several compliance measures, including a
readiness to comply scale, a pros and cons scale, a pro-
cesses scale, and a temptation to skip medication scale
were administered to 731 hypertensive patients, who also
reported their compliance in the last four weeks.
RESULTS: Readiness to comply was highly related to re-
ported compliance (contingency coefficient = .72, p <
.0001). As readiness to comply increased, overall level of
temptations decreased and patients rated the positive as-
pects of compliance or the pros higher and the negatives
or cons lower and used different processes of change.
CONCLUSIONS: Behavior change compliance measures
are related to self-reported compliance. Utilizing these
measures will improve assessment of an individual's
readiness to comply and permit creation of customized
interventions for individual patients.
